Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine
Cortes, Javier × Vahdat, Linda Blum, Joanne L Twelves, Chris Campone, Mario Roché, Henri Bachelot, Thomas Awada, Ahmad Paridaens, Robert Goncalves, Anthony Shuster, Dale E Wanders, Jantien Fang, Fang Gurnani, Renuka Richmond, Elaine Cole, Patricia E Ashworth, Simon Allison, Mary Ann #
Grune & Stratton
Journal of Clinical Oncology vol:28 issue:25 pages:3922-3928
The activity and safety of eribulin mesylate (E7389), a nontaxane microtubule dynamics inhibitor with a novel mechanism of action, were evaluated in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, taxane, and capecitabine.